Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Diagnoplex secures 1.3 million Swiss francs from financing round

Diagnoplex SA, a developer of molecular diagnostics for colon cancer and Debiopharm Diagnostics SA, part of the Swiss-based global biopharmaceutical group of companies Debiopharm Group™, with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that Diagnoplex has secured 1.3 million Swiss francs from a financing round led by Debiopharm.

7 Jun 2013

Echo Therapeutics declares reverse split of issued and outstanding common stock

Echo Therapeutics, Inc., a company developing its needle-free Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that a 1-for-10 reverse split of the Company's issued and outstanding common stock will be effective prior to the market opening on Friday, June 7, 2013.

7 Jun 2013

Echo Therapeutics to evaluate safety, efficacy of Symphony CGM System in hospital setting

Echo Therapeutics, Inc., a company developing its needle-free Symphony CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it is initiating a multi-center clinical trial of its Symphony CGM System to support a CE Mark Technical File for marketing approval in Europe.

5 Jun 2013

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.

4 Jun 2013

Arcturus Therapeutics closes $1.3 M in seed funding round

Arcturus Therapeutics, Inc., an industry leader in RNAi technologies for the treatment of disease, today announced it has raised $1.3 million in a seed funding round led by multiple high net-worth private investors from the United States and Canada.

3 Jun 2013

Study: GLT1 protein plays a critical role in cocaine craving

A new study conducted by a team of Indiana University neuroscientists demonstrates that GLT1, a protein that clears glutamate from the brain, plays a critical role in the craving for cocaine that develops after only several days of cocaine use.

3 Jun 2013

Depomed receives complete response letter for SEFELSA NDA

Depomed, Inc., a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration issued a complete response letter to the New Drug Application for SEFELSA, Depomed's investigational, oral, twice daily formulation of gabapentin to treat moderate to severe vasomotor symptoms due to menopause.

1 Jun 2013

University of Strathclyde uses new imaging technique to track nanomedicines' effects on patients

A pioneering imaging technique to track the effects of next-generation nanomedicines on patients has been harnessed by a University of Strathclyde academic.

31 May 2013

Strengthening miniaturized titanium-based medical devices: an interview with Dr Masaru Rao, University of California, Riverside

While titanium is used widely for more conventional macro-scale medical devices (e.g. hip implants, dental implants, and cardiac pacemakers), its use for micro- and nano-scale devices has been limited thus far.

29 May 2013

Teh Seng’s generic Lidoderm manufacturing facility in Taiwan successfully completes FDA cGMP audit

TWi Pharmaceuticals, Inc., today announced that Teh Seng Pharmaceutical Mfg. Co., the manufacturing partner for its generic version of Lidoderm (5% lidocaine patch) located in Taiwan, has completed the cGMP audit and pre-approval inspection by US Food and Drug Administration and been granted "acceptable" status under the FDA's regulatory guidelines.

29 May 2013

Echo Therapeutics unveils Symphony CGM System

Echo Therapeutics, Inc., a company developing its needle-free Symphony CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced the successful unveiling and demonstration of its Symphony CGM System during a live webcast following yesterday's annual stockholders meeting.

24 May 2013

Cenix BioScience, Debiopharm partner to develop novel therapeutic drug candidates

Cenix BioScience, a leading preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that they have signed a research agreement to support Debiopharm in its ongoing efforts to develop novel therapeutic drug candidates.

23 May 2013

New drug delivery system can help treat lung cancer

Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage done to other organs while significantly improving the treatment of lung tumors.

23 May 2013

Innovative nebulizer to treat cystic fibrosis developed by Cambridge Consultants

Observing surfers with cystic fibrosis (CF) led scientists to discover that the inhaled mist of seawater has a therapeutic effect on the lung problems associated with the disease. Now the findings have been used by pharmaceutical company Parion Sciences and product development firm Cambridge Consultants in a revolutionary new aerosol delivery system. It enables CF sufferers to get the benefits of saltwater treatment in their own homes overnight while they sleep.

23 May 2013

Researchers develop new method for delivering molecules into targeted single cells through temporary holes

Northwestern University researchers have developed a new method for delivering molecules into single, targeted cells through temporary holes in the cell surface. The technique could find applications in drug delivery, cell therapy, and related biological fields.

22 May 2013

Study analyzes potential usefulness of new treatment to reopen clogged arteries

Over the past few decades, scientists have developed many devices that can reopen clogged arteries, including angioplasty balloons and metallic stents.

22 May 2013

Clinical trial of Echo Therapeutics' Symphony CGM System receives IRB approval

Echo Therapeutics, Inc., a company developing its needle-free Symphony CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, announced today that the Company's clinical trial of its Symphony CGM System has received Institutional Review Board approval.

21 May 2013

Grifols signs worldwide licensing agreement for Aradigm's Pulmaquin

Grifols, S.A. and Aradigm Corporation today announced the signing of an exclusive, worldwide license for Aradigm's proprietary formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin) for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis.

21 May 2013

Recombinant human albumin from Novozymes Biopharma helps innovative dry eye therapy move into clinical trials

Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, today announced that an ophthalmic solution made using its recombinant human albumin, has been approved for Phase I/II development by the FDA.

20 May 2013

FDA clears Oramed Pharmaceuticals' IND for ORMD-0801

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration has cleared the Company's Investigational New Drug application for ORMD-0801, its oral insulin capsule.

17 May 2013

Drug Delivery News and Research

Further Reading

Diagnoplex secures 1.3 million Swiss francs from financing round

Echo Therapeutics declares reverse split of issued and outstanding common stock

Echo Therapeutics to evaluate safety, efficacy of Symphony CGM System in hospital setting

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Arcturus Therapeutics closes $1.3 M in seed funding round

Study: GLT1 protein plays a critical role in cocaine craving

Depomed receives complete response letter for SEFELSA NDA

University of Strathclyde uses new imaging technique to track nanomedicines' effects on patients

Strengthening miniaturized titanium-based medical devices: an interview with Dr Masaru Rao, University of California, Riverside

Teh Seng’s generic Lidoderm manufacturing facility in Taiwan successfully completes FDA cGMP audit

Echo Therapeutics unveils Symphony CGM System

Cenix BioScience, Debiopharm partner to develop novel therapeutic drug candidates

New drug delivery system can help treat lung cancer

Innovative nebulizer to treat cystic fibrosis developed by Cambridge Consultants

Researchers develop new method for delivering molecules into targeted single cells through temporary holes

Study analyzes potential usefulness of new treatment to reopen clogged arteries

Clinical trial of Echo Therapeutics' Symphony CGM System receives IRB approval

Grifols signs worldwide licensing agreement for Aradigm's Pulmaquin

Recombinant human albumin from Novozymes Biopharma helps innovative dry eye therapy move into clinical trials

FDA clears Oramed Pharmaceuticals' IND for ORMD-0801

Event guide: World ADC San Diego eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo